Remission of persistent methamphetamine-induced psychosis after electroconvulsive therapy: Presentation of a case and review of the literature

American Journal of Psychiatry

Volumn 167, Issue 1, 2010, Pages 17-23

  Grelotti, David J ^a   Kanayama, Gen ^a   Pope Jr , Harrison G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; METHAMPHETAMINE; OLANZAPINE; QUETIAPINE;

ADULT; ANAMNESIS; AUDITORY HALLUCINATION; CASE REPORT; CLINICAL FEATURE; CONFERENCE PAPER; DRUG ABUSE; DRUG DOSE TITRATION; ELECTROCONVULSIVE THERAPY; HUMAN; MALE; PARANOIA; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOTHERAPY; REMISSION; SUBSTANCE ABUSE;

ADULT; AMPHETAMINE-RELATED DISORDERS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; ELECTROCONVULSIVE THERAPY; HUMANS; MALE; METHAMPHETAMINE; PSYCHOSES, SUBSTANCE-INDUCED; TREATMENT OUTCOME;

EID: 73949111718     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2009.08111695     Document Type: Conference Paper

References (65)

1. United Nations Office on Drugs and Crime: Amphetamines and Ecstasy: 2008 Global ATS Assessment. Vienna, United Nations Office on Drugs and Crime, 2008 (http://www.unodc.org/documents/scientific/ATS/Global-ATS-Assessment-2008-Web. pdf)
2. Substance Abuse and Mental Health Services Administration Office of Applied Studies: Results from the 2007 National Survey on Drug Use and Health: Detailed tables (Table 1.1A). Rockville, Md, Substance Abuse and Mental Health Services Administration (http://www.oas.samhsa.gov/NSDUH/2k7NSDUH/tabs/ Sect1peTabs1to46.htm#Tab1.1A.)
3. Kraman P: Drug abuse in America: rural meth, in TrendsAlert: Critical Information for State Decision-Makers. Lexington, Ky, Council of State Governments, 2004 (http://www.csg.org/pubs/Documents/TA0403RuralMeth.pdf)
4. Cunningham JK, Liu LM: Impact of methamphetamine precursor chemical legislation, a suppression policy, on the demand for drug treatment. Soc Sci Med 2008; 66:1463-1473
5. Substance Abuse and Mental Health Services Administration Office of Applied Studies: Treatment Episode Data Set (TEDS): 1992-2002: National Admissions to Substance Abuse Treatment Services, DASIS Series S-23. DHHS Publication No. SMA 04-3965. Rockville, Md, Substance Abuse and Mental Health Services Administration, Sept 2004 (http://wwwdasis.samhsa.gov/teds02/2002-teds- rpt.pdf)
6. Substance Abuse and Mental Health Services Administration Office of Applied Studies: Treatment Episode Data Set (TEDS): Highlights, 2006: National Admissions to Substance Abuse Treatment Services, DASIS Series S-40. DHHS Publication No. SMA 08-4313. Rockville, Md, Substance Abuse and Mental Health Services Administration, Jan 2008 (http://www.oas.samhsa.gov/teds2k6highlights/ teds2k6highWeb.pdf)
7. Substance Abuse and Mental Health Services Administration Office of Applied Studies: Drug Abuse Warning Network, 2005: National Estimates of Drug-Related Emergency Department Visits. DAWN Series D-29, DHHS Publication No. SMA 07-4256. Rockville, Md, Substance Abuse and Mental Health Services Administration, Aug 2008 (http://dawninfo.samhsa.gov/files/ED2006/DAWN2k6ED.pdf)
8. Hendrickson RG, Cloutier R, McConnell KJ: Methamphetamine-related emergency department utilization and cost. Acad Emerg Med 2008; 15:23-31
9. Swanson SM, Sise CB, Sise MJ, Sack DI, Holbrook TL, Paci GM: The scourge of methamphetamine: impact on a level I trauma center. J Trauma 2007; 63:531-537
10. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ: Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry 2005; 13:141-154
11. Rawson RA, Ling W: Clinical management: methamphetamine, in Textbook of Substance Abuse Treatment, 4th ed. Edited by Galanter M, Kleber HD. Washington, DC, American Psychiatric Publishing, 2008, pp 169-179
12. Connell PH: Amphetamine Psychosis. London, Chapman & Hall, 1958
13. Hayashi S: Chronic methamphetamine addiction. Sogo-Igaku 1955; 12:656-661 ( Japanese)
14. Akiyama K: Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence. Ann NY Acad Sci 2006;1074:125-134
15. Iwanami A, Sugiyama A, Kuroki N, Toda S, Kato N, Nakatani Y, Horita N, Kaneko T: Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan: a preliminary report. Acta Psychiatr Scand 1994; 89:428-432
16. Konuma K: Multiphasic clinical types of methamphetamine psychosis and its dependence. Seishin Shinkeigaku Zasshi 1984; 86:315-339 ( Japanese)
17. Matsumoto T: Clinical features of recent methamphetamine abusers: comparison between smoking abusers and injection abusers. Seishin Shinkeigaku Zasshi 2000; 102:498-513 (Japanese)
18. Matsumoto T, Kamijo A, Miyakawa T, Endo K, Yabana T, Kishimoto H, Okudaira K, Iseki E, Sakai T, Kosaka K: Methamphetamine in Japan: the consequences of methamphetamine abuse as a function of route of administration. Addiction 2002; 97:809-817
19. Nakatani Y, Yoshizawa F, Yamada H, Iwanami A, Sakaguchi M, Katoh N: Methamphetamine psychosis in Japan: a survey. Br J Addict 1989; 84:1548-1549
20. Ozaki S: Current situation of substance abuse/dependence in psychiatric hospital settings. Nihon Arukoru Yakubutsu Igakkai Zasshi [Japanese Journal of Alcohol Studies and Drug Dependence] 2004; 39:35-40 ( Japanese)
21. Sato M: Basic and clinical studies on methamphetamine-related psychosis. Seishin Shinkeigaku Zasshi [Psychiatria et Neurologia Japonica] 2002; 104:179-209 ( Japanese)
22. Sato M, Nakajima T, Otsuki S: A clinical study of chronic methamphetamine psychoses. Seishin Igaku 1982; 24:481-489 (Japanese)
23. Tatetsu S, Goto A, Fujiwara T: The Methamphetamine Psychosis. Tokyo, Igaku-Shoin, 1956 ( Japanese)
24. Teraoka A: A study on methamphetamine psychosis in a psychiatric clinic: comparison of acute and chronic-type cases. Seishin Shinkeigaku Zasshi 1998; 100:425-468 ( Japanese)
25. Tohhara S, Miyamoto Y, Nakajima T: Induced insanity occurring in hospitalized patients of chronic methamphetamine psychosis. Arukoru Kenkyuto Yakubutsu Ison 1985; 20:350-358 ( Japanese)
26. Wada K, Fukui S: Relationship between years of methamphetamine use and symptoms of methamphetamine psychosis. Arukoru Kenkyuto Yakubutsu Ison 1990; 25:143-158 (Japanese)
27. Yukitake A: Amphetamine psychosis in Tokyo: its clinical features and social problems. Folia Psychiatr Neurol Jpn 1983; 37:115-120
28. Teraoka A: Prognostic and criminological studies on mental disorder caused by chronic methamphetamine intoxication. Seishin Shinkeigaku Zasshi 1967; 69:597-619 ( Japanese)
29. Ujike H, Sato M: Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann NY Acad Sci 2004; 1025:279-287
30. Yui K, Ikemoto S, Goto K, Nishijima K, Yoshino T, Ishiguro T: Spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory states in female subjects: susceptibility to psychotic states and implications for relapse of schizophrenia. Pharmacopsychiatry 2002; 35:62-71
31. Salo R, Nordahl TE, Leamon MH, Natsuaki Y, Moore CD, Waters C, Carter CS: Preliminary evidence of behavioral predictors of recurrent drug-induced psychosis in methamphetamine abuse. Psychiatry Res 2008; 157:273-277
32. Martin WR, Sloan JW, Sapira JD, Jasinski DR: Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971; 12:245-258
33. Sevak RJ, Stoops WW, Hays LR, Rush CR: Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans. J Pharmacol Exp Ther 2009;328:1007-1018
34. Poulton A: Long-term outcomes of stimulant medication in attention-deficit hyperactivity disorder. Expert Rev Neurother 2006; 6:551-561
35. Rappley MD: Clinical practice: attention deficit-hyperactivity disorder. N Engl J Med 2005; 352:165-173
36. McKetin R, McLaren J, Lubman DI, Hides L: The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006; 101:1473-1478
37. Mahoney JJ 3rd, Kalechstein AD, De La Garza R 2nd, Newton TF: Presence and persistence of psychotic symptoms in cocaine-versus methamphetamine- dependent participants. Am J Addict 2008; 17:83-98
38. Sato M: Acute exacerbation of methamphetamine psychosis and lasting dopaminergic supersensitivity: a clinical survey. Psychopharmacol Bull 1986; 22:751-756
39. Sato M: A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Ann NY Acad Sci 1992; 654:160-170
40. Sato M, Chen CC, Akiyama K, Otsuki S: Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 1983; 18:429-440
41. Yui K, Goto K, Ikemoto S, Nishijima K, Yoshino T, Ishiguro T: Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis. Drug Alcohol Depend 2001; 64:133-142
42. Takezaki H, Inotani T, Ikeda T, Yasuoka T: A case of acute recurrent methamphetamine psychosis characterized by fancy delusions of grandeur. Seishin Shinkeigaku Zasshi 1984; 86:621-630 (Japanese)
43. Sato M: An experimental study of onset and relapse mechanisms of chronic methamphetamine psychosis. Seishin Shinkeigaku Zasshi 1979; 81:21-32 ( Japanese)
44. Yui K, Ikemoto U, Goto K: Spontaneous recrudescence of psychotic diseases caused by methamphetamine (a stimulant): the stress type and the role of noradrenaline and dopamine systems. Nihon Shinkei Seishin Yakurigaku Zasshi 2004; 24:319-320 ( Japanese)
45. Boutros NN, Bowers MB Jr: Chronic substance-induced psychotic disorders: state of the literature. J Neuropsychiatry Clin Neurosci 1996; 8:262-269
46. Fujii D: Risk factors for treatment-resistive methamphetamine psychosis. J Neuropsychiatry Clin Neurosci 2002; 14:239-240
47. Chen CK, Lin SK, Sham PC, Ball D, Loh EW, Hsiao CC, Chiang YL, Ree SC, Lee CH, Murray RM: Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Med 2003; 33:1407-1414
48. Chen CK, Lin SK, Sham PC, Ball D, Loh el-W, Murray RM: Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. Am J Med Genet B Neuropsychiatr Genet 2005; 136B:87-91
49. Hanson GR, Rau KS, Fleckenstein AE: The methamphetamine experience: a NIDA partnership. Neuropharmacology 2004; 47(suppl 1):92-100
50. Shoptaw SJ, Kao U, Ling WW: Treatment for amphetamine psychosis. Cochrane Database Syst Rev 2008(4):CD003026
51. Leelahanaj T, Kongsakon R, Netrakom P: A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. J Med Assoc Thai 2005; 88(suppl 3):S43-S52
52. Misra L, Kofoed L: Risperidone treatment of methamphetamine psychosis (letter). Am J Psychiatry 1997; 154:1170
53. Misra LK, Kofoed L, Oesterheld JR, Richards GA: Olanzapine treatment of methamphetamine psychosis. J Clin Psychopharmacol 2000; 20:393-394
54. Seiden LS, Fischman MW, Schuster CR: Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend 1976; 1:215-219
55. Wagner GC, Seiden LS, Schuster CR: Methamphetamine-induced changes in brain catecholamines in rats and guinea pigs. Drug Alcohol Depend 1979; 4:435-438
56. Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK: Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 2003; 28:1730-1740
57. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ: Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 1996; 2:699-703
58. Glue P, Costello MJ, Pert A, Mele A, Nutt DJ: Regional neurotransmitter responses after acute and chronic electroconvulsive shock. Psychopharmacology (Berl) 1990; 100:60-65
59. Lisanby SH, Belmaker RH: Animal models of the mechanisms of action of repetitive transcranial magnetic stimulation (RTMS): comparisons with electroconvulsive shock (ECS). Depress Anxiety 2000; 12:178-187
60. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, Hitzemann R, Ding YS, Logan J: Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 2001; 21:9414-9418
61. Marshall JF, Belcher AM, Feinstein EM, O'Dell SJ: Methamphetamine-induced neural and cognitive changes in rodents. Addiction 2007; 102(suppl 1):61-69
62. Nakajima K, Yamazaki K, Moriya H: Current problems with attitudes and informed consent on ECT: a questionnaire survey of psychiatrists. Seishin Shinkeigaku Zasshi 1993; 95:537-554 ( Japanese)
63. Freudenmann RW, Schonfeldt-Lecuona C, Spitzer M, Hermle L, Gron G: Electroconvulsive therapy in the treatment of depression in a former Ecstasy user. J Psychopharmacol 2006; 20:860-862
64. Jaffe C, Bush KR, Straits-Troster K, Meredith C, Romwall L, Rosenbaum G, Cherrier M, Saxon AJ: A comparison of methamphetamine-dependent inpatients childhood attention deficit hyperactivity disorder symptomatology. J Addict Dis 2005; 24:133-152
65. McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J, Ye W, Alexander M, Dannals RF, Wong DF, Ricaurte GA: Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 2008; 62:91-100